I started my Insights career at a medical devices division of one of the ...
As the drug landscape grows increasingly competitive, it will be vital to gain an ...
Since 2020, diversity, equity, and inclusion (DE&I) has been a prime area of attention ...
In many respects, the arrival of generative artificial intelligence (AI) represents an entirely expected ...
An initial and discernible benefit to adopting decentralized clinical trial (DCT) models is alleviating ...
PM360 asked six CEOs at companies developing cancer treatments to provide an update on ...
Over 300 drugs in the U.S. are in limited supply or unavailable, marking the worst ...
According to the National Organization for Rare Disorders (NORD), there are over 7,000 known ...
The world is full of tradeoffs—it’s the way progress is made while proportionately managing ...
2023 is poised to be a transformative year for the pharma industry, even more ...
Getting clinical trials to the finish line is not easy. Between 15% to 40% ...
PM360 asked experts in clinical trials about the evolution of decentralized research and what ...
Clinical trial protocol writing teams usually start with scientific objectives, and ideally with the ...